|
|
|
| Application value of double contrast-enhanced ultrasonography in the evaluation of efficacy of neoadjuvant chemotherapy for gastric cancer with liver metastasis |
| WU Wei1 YANG Jianjun1 FAN Huihui1 SHI Linfeng1 MO Danfei1 HU Mingfang2 |
1.Department of Ultrasonography, Central Hospital of Huzhou City, Zhejiang Province, Huzhou 310013, China;
2.Department of Radiology, Central Hospital of Huzhou City, Zhejiang Province, Huzhou 310013, China |
|
|
|
Abstract Objective To investigate the application value of double contrast-enhanced ultrasonography in the efficacy evaluation of neoadjuvant chemotherapy for gastric cancer with liver metastasis (GCLM). Methods A retrospective analysis of the clinical data of 80 cases of with GCLM who received neoadjuvant chemotherapy in Central Hospital of Huzhou City, Zhejiang Province, from August 2016 to October 2017. All the cases were divided into effective group (54 cases) and progressive group (26 cases) according to clinical efficacy. The microvascular density (MVD) and peak intensity (PI), rising time (RT), time to peak (TTP), enhancement intensity (EI) were compared between the two groups after treatment, and the correlation between double contrast parameters and MVD was analyzed. Results After treatment, PI and EI of all the patients were significantly lower than those before treatment (P ＜ 0.05), and RT and TTP were significantly higher than those before treatment (P ＜ 0.05). After treatment, the MVD in progressive groups was significantly higher than that in the effective group, the difference was statistically significant (P ＜ 0.05). Through correlation analysis, MVD was positively correlated with PI and EI (rPI = 0.275, P = 0.013; rEI = 0.436, P = 0.000), and were negatively correlated with RT and TTP MVD (rRT = -0.287, P = 0.021; rTTP = -0.320, P = 0.047). Conclusion Ultrasound double contrast-enhanced parameters of PI and EI can be used to evaluate the efficacy of neoadjuvant chemotherapy for GCLM, which have high sensitivity.
|
|
|
|
|
|
[1] Shachar L，Michael OM，Hong JK. Surveillance for Gastric Cancer [J]. Surg Clin North Am，2017，97（2）：317-331.
[2] 杨洁，李连顺，武赞凯，等.胃癌肝转移治疗进展[J].兰州大学学报：医学版，2015，41（2）：15-19.
[3] Karol RP，Johanna WS，Jerzy M，et al. Current challenges in gastric cancer surgery：European perspective [J]. Surg Oncol，2018，27（4）：650-656.
[4] 李子禹，苗儒林，季加孚.胃癌规范化新辅助化疗[J].中国实用外科杂志，2014，34（7）：627-629.
[5] 万学红，卢雪峰.诊断学[M].8版.北京：人民卫生出版社，2013：321-323.
[6] Chen J，Tang Z，Dong X，et al. Radiofrequency ablation for liver metastasis from gastric cancer [J]. Eur J Surg Oncol，2013，39（7）：701-706.
[7] 胡晓，陈子洋.胃癌肝转移患者的临床特征及预后生存分析[J].医学研究生学报，2017，30（2）：169-172.
[8] Tiberio GAM，Ministrini S，Gardini A，et al. Factors influencing survival after hepatectomy for metastases from gastric cancer [J]. Eur J Surg Oncol，2016，42（8）：1229-1235.
[9] 陈凛，郗洪庆，李佶阳.胃癌肝转移规范化治疗[J].中国实用外科杂志，2014，34（7）：619-621.
[10] Erin KG，Christopher SH，Joyce W. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer： Evidence from the American College of Surgeons National Cancer Database [J]. Surg，2016，159（4）：1099-1112.
[11] 王乐华，黄旴宁，刘艳婷，等.超声双重造影对评判及预测胃癌伴肝转移新辅助化疗的价值[J].中国地方病防治杂志，2017，32（8）：915-916.
[12] Marano L，Polom K，Patriti A，et al. Surgical management of advanced gastric cancer：An evolving issue [J]. Eur J Surg Oncol，2016，42（1）：18-27.
[13] Louis DM，Sophie LD，Julien V，et al. Recent insights in the therapeutic management of patients with gastric cancer [J]. Digest Liver Dis，2016，48（9）：984-994.
[14] Karol P，Christine B，Elizabeth S，et al. Synchronous me-tastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency [J]. Eur J Surg Oncol，2018，44（5）：626-631.
[15] 李斌.超声双重造影参数对预测及评判胃癌伴肝转移新辅助化疗效果的价值[J].中国卫生工程学，2018，17（1）：85-87.
[16] 徐娟，赵晔，李俊芝，等.超声双重造影对胃癌伴肝内转移患者新辅助化疗疗效预测的价值研究[J].中国医学装备，2016，13（4）：71-75.
[17] Jie D，Lin C，Tai PZ，et al. Pancreatic metastasis of renal cell carcinoma [J]. Hbpd Int，2016，15（1）：30-38.
[18] 熊清泉，王道荣，梁勇.胃癌肝转移的分子机制研究进展及综合治疗[J].世界华人消化杂志，2016，24（18）：2823-2829.
[19] Yamashita K，Ushiku H，Katada N，et al. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test [J]. Eur J Surg Oncol，2015，41（10）：1324-1332.
[20] Giuseppe A，Elena O，Marzia DR，et al. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas： A critical insight [J]. Crit Rev Oncol Hemat， 2015，95（2）：165-178. |
|
|
|
